Patents by Inventor Hui-Fang Chang

Hui-Fang Chang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED INDAZOLES AS IRAK4 INHIBITORS
    Publication number: 20240182479
    Abstract: The present application relates to chemical compounds of Formula (I), and pharmaceutically acceptable salts thereof, that inhibit IRAK4 and consequently have potential utility in medicine.
    Type: Application
    Filed: November 2, 2023
    Publication date: June 6, 2024
    Inventors: Ina TERSTIEGE, Stefan SCHIESSER, Yafeng XUE, Hui-Fang CHANG, Anna Ingrid Kristina BERGGREN
  • Substituted indazoles as IRAK4 inhibitors
    Patent number: 11866405
    Abstract: The present application relates to chemical compounds of Formula (A): and pharmaceutically acceptable salts thereof, wherein X, R1, and R2 are as defined herein. The chemical compounds of Formula (A) inhibit IRAK4 and consequently have potential utility in medicine.
    Type: Grant
    Filed: December 1, 2021
    Date of Patent: January 9, 2024
    Assignee: AstraZeneca AB
    Inventors: Ina Terstiege, Stefan Schiesser, Yafeng Xue, Hui-Fang Chang, Anna Ingrid Kristina Berggren
  • IRAK4 INHIBITORS
    Publication number: 20220185817
    Abstract: The present application relates to chemical compounds of Formula (I), and pharmaceutically acceptable salts thereof, that inhibit IRAK4 and consequently have potential utility in medicine.
    Type: Application
    Filed: December 1, 2021
    Publication date: June 16, 2022
    Inventors: Ina TERSTIEGE, Stefan SCHIESSER, Yafeng XUE, Hui-Fang CHANG, Anna Ingrid Kristina BERGGREN
  • Cinnoline Compounds for the Treatment of Anxiety, Cognitive and Mood Disorders
    Publication number: 20110144331
    Abstract: This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of anxiety disorders, cognitive disorders, and/or mood disorders.
    Type: Application
    Filed: February 22, 2011
    Publication date: June 16, 2011
    Applicant: AstraZeneca AB
    Inventors: Marc J. Chapdelaine, Cyrus J. Ohnmacht, Christopher Becker, Hui-Fang Chang, Bruce T. Dembofsky
  • Nicotinic Acetylcholine Receptor Ligands 101
    Publication number: 20110136804
    Abstract: Nicotinic acetylcholine receptor ligands of Formula I wherein X, n, R1 and R2 are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing, and methods for using the same.
    Type: Application
    Filed: November 5, 2010
    Publication date: June 9, 2011
    Applicant: AstraZeneca AB
    Inventors: Hui-Fang Chang, Christopher Holmquist, Eifion Phillips, Timothy Piser, Thomas Simpson, Rebecca Urbanek, James Woods, Hui Xiong
  • Thienyl Compounds
    Publication number: 20110124672
    Abstract: Compounds of formula I: and pharmaceutically-acceptable salts thereof, wherein Ar and R are as defined in the specification, compositions containing such compounds and the use of such compounds and compositions for use in therapy.
    Type: Application
    Filed: October 27, 2010
    Publication date: May 26, 2011
    Applicant: AstraZeneca AB
    Inventors: Hui-Fang Chang, Yan Li, Eifion Phillips
  • Nicotinic acetylcholine receptor ligands 101
    Patent number: 7842803
    Abstract: Nicotinic acetylcholine receptor ligands of Formula I wherein X, n, R1 and R2 are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing, and methods for using the same.
    Type: Grant
    Filed: May 17, 2007
    Date of Patent: November 30, 2010
    Assignee: AstraZeneca AB
    Inventors: Hui-Fang Chang, Christopher Holmquist, Eifion Phillips, Timothy Piser, Thomas Simpson, Rebecca Urbanek, James Woods, Hui Xiong
  • Oxazolidinone nicotinic acetylcholine receptor agonists
    Patent number: 7514567
    Abstract: Compounds of formula I: and pharmaceutically-acceptable salts thereof, wherein Q, Ar1, A and Ar2 are as defined in the specification, pharmaceutical compositions and formulations containing them, methods of using them to treat diseases and conditions either alone or in combination with other therapeutically-active compounds or substances, processes and intermediates used to prepare them, uses of them as medicaments for therapy, uses of them in the manufacture of medicaments and uses of them for diagnostic and analytic purposes.
    Type: Grant
    Filed: July 6, 2004
    Date of Patent: April 7, 2009
    Assignee: AstraZeneca AB
    Inventors: Hui-Fang Chang, Eifion Phillips
  • Compounds and Uses Thereof
    Publication number: 20090036454
    Abstract: This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of anxiety disorders, cognitive disorders, and/or mood disorders.
    Type: Application
    Filed: July 9, 2008
    Publication date: February 5, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Marc J. Chapdelaine, Cyrus J. Ohnmacht, Christopher Becker, Hui-Fang Chang, Bruce T. Dembofsky
  • Compounds and Uses Thereof
    Publication number: 20090018112
    Abstract: This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of anxiety disorders, cognitive disorders, and/or mood disorders.
    Type: Application
    Filed: August 27, 2008
    Publication date: January 15, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Marc J. Chapdelaine, Cyrus J. Ohnmacht, Christopher Becker, Hui-Fang Chang, Bruce T. Dembofsky
  • Compounds and Uses Thereof - 848
    Publication number: 20080318943
    Abstract: This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof, wherein R1, R2, R3, R4, R5, and R6 are defined in the specification. These novel compounds provide a treatment or prophylaxis of anxiety disorders, schizophrenia, cognitive disorders, and/or mood disorders.
    Type: Application
    Filed: June 18, 2008
    Publication date: December 25, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Hui-Fang Chang, Marc Chapdelaine, Bruce Thomas Dembofsky, Keith John Herzog, Carey Horchler, Richard Jon Schmiesing
  • Compounds and uses thereof
    Patent number: 7465795
    Abstract: This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of anxiety disorders, cognitive disorders, and/or mood disorders.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: December 16, 2008
    Assignee: AstraZeneca AB
    Inventors: Marc J. Chapdelaine, Cyrus J. Ohnmacht, Christopher Becker, Hui-Fang Chang, Bruce T. Dembofsky
  • Compounds and uses thereof
    Patent number: 7425556
    Abstract: This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of anxiety disorders, cognitive disorders, and/or mood disorders.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: September 16, 2008
    Assignee: AstraZeneca AB
    Inventors: Marc J. Chapdelaine, Cyrus J. Ohnmacht, Christopher Becker, Hui-Fang Chang, Bruce T. Dembofsky
  • Heterocyclic compounds
    Patent number: 7417050
    Abstract: Compounds of formula I: and pharmaceutically-acceptable salts thereof, wherein Ar and R are as defined in the specification, compositions containing such compounds and the use of such compounds and compositions for use in therapy.
    Type: Grant
    Filed: April 15, 2003
    Date of Patent: August 26, 2008
    Assignee: AstraZeneca AB
    Inventors: Hui-Fang Chang, Eifion Phillips
  • Furyl compounds
    Patent number: 7417049
    Abstract: Compounds of formula I: and pharmaceutically-acceptable salts thereof, wherein Ar and R are as defined in the specification, compositions containing such compounds and methods of using such compounds and compositions in therapy.
    Type: Grant
    Filed: April 15, 2003
    Date of Patent: August 26, 2008
    Assignee: AstraZeneca AB
    Inventors: Hui-Fang Chang, Yan Li, Eifion Phillips
  • Nicotinic Acetylcholine Receptor Ligands 101
    Publication number: 20080139600
    Abstract: Nicotinic acetylcholine receptor ligands of Formula I wherein X, n, R1 and R2 are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing, and methods for using the same.
    Type: Application
    Filed: May 17, 2007
    Publication date: June 12, 2008
    Applicant: AstraZeneca AB
    Inventors: Hui-Fang Chang, Christopher Holmquist, Eifion Phillips, Timothy Piser, Thomas Simpson, Rebecca Urbanek, James Woods, Hui Xiong
  • Nicotinic Acetylcholine Receptor Ligands
    Publication number: 20080113983
    Abstract: Acetylcholine receptor ligands of formula I wherein A, Ar1 and Ar2 are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Application
    Filed: December 13, 2005
    Publication date: May 15, 2008
    Applicant: AstraZeneca AB
    Inventors: Marc Chapdelaine, Hui-Fang Chang, Keith J. Herzog, Carey Horchler, Eifion Phillips
  • Compounds and Uses Thereof
    Publication number: 20070142328
    Abstract: This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of anxiety disorders, cognitive disorders, and/or mood disorders.
    Type: Application
    Filed: December 18, 2006
    Publication date: June 21, 2007
    Applicant: AstraZeneca AB
    Inventors: Marc Chapdelaine, Cyrus Ohnmacht, Christopher Becker, Hui-Fang Chang, Bruce Dembofsky
  • Thienyl Compounds
    Publication number: 20070142419
    Abstract: Compounds of formula I: and pharmaceutically-acceptable salts thereof, wherein Ar and R are as defined in the specification, compositions containing such compounds and the use of such compounds and compositions for use in therapy.
    Type: Application
    Filed: January 29, 2007
    Publication date: June 21, 2007
    Inventors: Hui-Fang Chang, Yan Li, Eifion Phillips
  • Compounds and Uses Thereof
    Publication number: 20070142382
    Abstract: This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of anxiety disorders, cognitive disorders, and/or mood disorders.
    Type: Application
    Filed: December 18, 2006
    Publication date: June 21, 2007
    Applicant: AstraZeneca AB
    Inventors: Marc Chapdelaine, Cyrus Ohnmacht, Christopher Becker, Hui-Fang Chang, Bruce Dembofsky